Study With GFT505 (80mg) Versus Placebo in Patients With Type 2 Diabetes Mellitus

PHASE2CompletedINTERVENTIONAL
Enrollment

97

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions
Type II Diabetes Mellitus
Interventions
DRUG

GFT505 80mg

hard gelatin capsules dosed at 20mg,oral administration,4 capsules per day before breakfast

DRUG

Placebo

hard gelatin capsules,oral administration,4 capsules per day before breakfast

Trial Locations (28)

1000

Site n°31, Skopje

Site n°32, Skopje

2025

Site n°42, Chisinau

2068

Site n°43, Chisinau

3112

Site n°41, Bălţi

7000

Site n°33, Bitola

11000

Site n°52, Belgrade

Site n°53, Belgrade

Site n°56, Belgrade

18000

Site n°51, Niš

34000

Site n°54, Kragujevac

71000

Site n°11, Sarajevo

78000

Site n°12, Banja Luka

100163

Site n°71, Ploieşti

100342

Site n°70, Ploieşti

120203

Site n°66, Buzău

400006

Site n°64, Cluj-Napoca

410167

Site n°72, Oradea

430123

Site n°65, Baia Mare

540098

Site n°63, Târgu Mureş

540142

Site n°62, Târgu Mureş

550245

Site n°61, Sibiu

LV 1002

Site n°22, Riga

LV 1004

Site n°21, Riga

LV4201

Site n°23, Valmiera

020045

Site n°67, Bucharest

Site n°69, Bucharest

020475

Site n°68, Bucharest

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Genfit

INDUSTRY

NCT01261494 - Study With GFT505 (80mg) Versus Placebo in Patients With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter